To evaluate long-term treatment outcomes of external beam radiotherapy for prostate cancer with a pretreatment prostate-specific antigen (PSA) level of more than 50 ng/ml and without evidence of lymph node or distant metastasis.
Definitive radiotherapy of 66 Gy or 72 Gy in combination with androgen deprivation therapy (ADT) was performed. PSA relapse-free survival (PRFS), distant metastasis-free survival (DMFS), cause-specific survival (CSS), and overall survival (OS) were evaluated. The impact of prognostic factors on PRFS, DMFS, CSS, and OS was analyzed in univariate and multivariate analyses.
One hundred twenty patients with a median follow-up period of 92.6 months were analyzed in this study. The median duration of ADT was 11.0 months. The 5- and 8-year PRFS rates in all patients were 65.1% and 48.5%, respectively. The 8-year DMFS, CSS, and OS rates in all patients were 84.0%, 93.4%, and 81.6%, respectively. Both in univariate and multivariate analyses, Gleason score (GS) and radiotherapy dose were significant prognostic factors (p=0.015 and 0.001). There was no significant difference between each prognostic factor in DMFS, CSS, and OS.
We might have indicated the significance of definitive radiotherapy even for prostate cancer with PSA of more than 50 ng/ml and without evidence of metastasis.
Anticancer research. 2018 Apr [Epub]
Rei Umezawa, Koji Inaba, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Satoshi Shima, Keisuke Tsuchida, Tairo Kashihara, Kazuma Kobayashi, Ken Harada, Kana Takahashi, Naoya Murakami, Yoshinori Ito, Hiroshi Igaki, Keiichi Jingu, Jun Itami
Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan ., Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan., Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.